Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of ...

Andrew Peters - UBS Good morning and welcome everyone to the second day of the 2012 UBS Global Life Sciences conference. My name is Andrew Peters and I’m a member of the biotech research team here at ...

Shares are trading flat year to date and the stock remains solidly in value territory, even in the absence of near-term drivers. Clinical trial collaborations with Merck and Bristol-Myers Squibb bode ...

Clinical trial results from Array BioPharma's (Nasdaq: ARRY) wholly-owned MEK inhibitor, binimetinib, and BRAF inhibitor, encorafenib, were presented this weekend at the European Society of Medical ...

Array BioPharma (Nasdaq: ARRY) today reported top-line results from the ongoing Phase 3 clinical trial of binimetinib in patients with advanced NRAS-mutant melanoma, known as the NEMO trial. The study ...

Pfizer Inc. (NYSE:PFE) today announced the successful completion of its acquisition of Array BioPharma Inc., advancing breakthrough science for the discovery, development and commercialization of ...

Shares of Array Biopharma Inc ARRY, a biopharmaceutical company that focuses on drugs to treat patients suffering from cancer, lost more than 12 percent early Monday morning after announcing a ...

NEW YORK (Reuters) - Array BioPharma Inc on Thursday sued AstraZeneca AB , accusing the pharmaceutical company of refusing to pay required royalties for a cancer drug after entering into an $8.5 ...

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. So what: Normally ...

SAN FRANCISCO (MarketWatch) -- Array BioPharma said Thursday night that it has expanded a collaboration agreement with Genentech Inc. to develop small molecule drugs against an additional protein ...

* Array Biopharma Inc - ‍FDA informed array that based on their preliminary review of applications they have not identified any potential review issues * Array Biopharma Inc - ‍FDA set a target action ...

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of ...